Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Infectious Agents and Cancer
Published in: Infectious Agents and Cancer 1/2016

Open Access 01-12-2016 | Short Report

A Case of Epididymo-orchitis after intravesical bacille Calmette-Guérin therapy for superficial bladder carcinoma in a patient with latent tuberculosis infection

Authors: C. Colomba, P. Di Carlo, G. Guadagnino, L. Siracusa, M. Trizzino, C. Gioè, A. Cascio

Published in: Infectious Agents and Cancer | Issue 1/2016

Login to get access

Abstract

Background

Intravesical instillation of bacille Calmette-Guérin (BCG) has been established as efficient therapy for superficial bladder carcinoma. Overall, intravesical BCG is well tolerated and results in complications of less than 5 %. However, adverse effects such as granulomatous prostatitis, pneumonitis, hepatitis, sepsis, and hypersensitivity reactions may occur. The reported rate for tuberculous orchitis after BCG intravesical therapy is 0.4 %.

Findings

We report a case of monolateral tuberculous orchitis occurring one month after the second course of intravescical instillation of bacille Calmette-Guérin in a patient with proven superficial bladder carcinoma and latent tuberculosis infection.

Conclusions

In our opinion intravesical instillation of BCG should be considered on an individual patient basis, with full patient disclosure of the potentially significant risks. A screening with an intradermal Mantoux before starting the first cycle of BCG instillation should be recommended and isoniazid would be indicated as the treatment for latent tuberculosis infection.
Literature
1.
Lamm DL. Efficacy and safety of bacille Calmette-Guerin immunotherapy in superficial bladder cancer. Clin Infect Dis. 2000;31 Suppl 3:S86–90.CrossRefPubMed
2.
Vazquez-Lavista LG, Flores-Balcazar CH, Llorente L. The bacillus Calmette-Guerin as immunomodulator in bladder cancer. Rev Invest Clin. 2007;59:146–52.PubMed
3.
Houghton BB, Chalasani V, Hayne D, et al. Intravesical chemotherapy plus bacille Calmette-Guerin in non-muscle invasive bladder cancer: a systematic review with meta-analysis. BJU Int. 2013;111:977–83.CrossRefPubMed
4.
5.
Gonzalez OY, Musher DM, Brar I, et al. Spectrum of bacille Calmette-Guerin (BCG) infection after intravesical BCG immunotherapy. Clin Infect Dis. 2003;36:140–8.CrossRefPubMed
6.
Dabrowska M, Drabarek T, Muraszko-Klaudel A, et al. A thoracic tuberculous spondylodisctis after intravesical BCG immunotherapy of bladder cancer - Case report and literature review. Neurol Neurochir Pol. 2015;49:460–6.PubMed
7.
Prescott S, Jackson AM, Hawkyard SJ, et al. Mechanisms of action of intravesical bacille Calmette-Guerin: local immune mechanisms. Clin Infect Dis. 2000;31 Suppl 3:S91–3.CrossRefPubMed
8.
Herr HW, Schwalb DM, Zhang ZF, et al. Intravesical bacillus Calmette-Guerin therapy prevents tumor progression and death from superficial bladder cancer: ten-year follow-up of a prospective randomized trial. J Clin Oncol. 1995;13:1404–8.PubMed
9.
Cookson MS, Herr HW, Zhang ZF, et al. The treated natural history of high risk superficial bladder cancer: 15-year outcome. J Urol. 1997;158:62–7.CrossRefPubMed
10.
Perez-Jacoiste Asin MA, Fernandez-Ruiz M, Lopez-Medrano F, et al. Bacillus Calmette-Guerin (BCG) infection following intravesical BCG administration as adjunctive therapy for bladder cancer: incidence, risk factors, and outcome in a single-institution series and review of the literature. Medicine (Baltimore). 2014;93:236–54.CrossRefPubMedCentral
11.
Nam EY, Na SH, Kim SY, et al. Infected Aortic Aneurysm caused by Mycobacterium bovis after Intravesical Bacillus Calmette-Guerin Treatment for Bladder Cancer. Infect Chemother. 2015;47:256–60.CrossRefPubMedPubMedCentral
12.
13.
Haaff EO, Dresner SM, Ratliff TL, et al. Two courses of intravesical bacillus Calmette-Guerin for transitional cell carcinoma of the bladder. J Urol. 1986;136:820–4.PubMed
14.
van der Meijden AP, Brausi M, Zambon V, et al. Intravesical instillation of epirubicin, bacillus Calmette-Guerin and bacillus Calmette-Guerin plus isoniazid for intermediate and high risk Ta, T1 papillary carcinoma of the bladder: a European Organization for Research and Treatment of Cancer genito-urinary group randomized phase III trial. J Urol. 2001;166:476–81.CrossRefPubMed
15.
Colombel M, Saint F, Chopin D, et al. The effect of ofloxacin on bacillus calmette-guerin induced toxicity in patients with superficial bladder cancer: results of a randomized, prospective, double-blind, placebo controlled, multicenter study. J Urol. 2006;176:935–9.CrossRefPubMed
Metadata
Title
A Case of Epididymo-orchitis after intravesical bacille Calmette-Guérin therapy for superficial bladder carcinoma in a patient with latent tuberculosis infection
Authors
C. Colomba
P. Di Carlo
G. Guadagnino
L. Siracusa
M. Trizzino
C. Gioè
A. Cascio
Publication date
01-12-2016
Publisher
BioMed Central
Published in
Infectious Agents and Cancer / Issue 1/2016
Electronic ISSN: 1750-9378
DOI
https://doi.org/10.1186/s13027-016-0072-y

Other articles of this Issue 1/2016

Infectious Agents and Cancer 1/2016 Go to the issue

Research Article

Diversity of high risk human papilloma viruses in women treated with antiretroviral and in healthy controls and discordance with cervical dysplasia in the South of Benin

Research Article

Changing Patterns of lung, liver, and head and neck non-AIDS-defining cancers relative to HIV status in Tanzania between 2002-2014

Research Article

Variants of human papillomaviruses 16 (HPV16) in Uigur women in Xinjiang, China

Erratum

Erratum to: Human papillomavirus types in non-cervical high-grade intraepithelial neoplasias and invasive carcinomas from San Luis Potosí, Mexico: a retrospective cross-sectional study

Review

Radio-frequency ablation-based studies on VX2rabbit models for HCC treatment

Erratum

Erratum to: Molecular Detection of Epstein - Barr virus in Nasopharyngeal Carcinoma among Sudanese population
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits